ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

NCT05622591 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Lack of Funding - no safety issue with Drug; Company Permanently Closed

Conditions

Acute Myeloid Leukemia
AML, Childhood
Relapsed Pediatric AML
Refractory Pediatric AML

Interventions

DRUG: ELU001

Sponsor

Elucida Oncology